Shenzhen Benliju Biotech Co., Ltd.
FDA issued a warning letter to Shenzhen Benliju Biotech Co., Ltd. (Shenzhen Shi, Guangdong Sheng, China) on Nov 6, 2026, citing 21 CFR 211.165, 21 CFR 211.100, 21 CFR 211.22, 21 CFR 211.160 and 1 more regulation. Subject: Request for Records, CGMP, Finished Pharmaceuticals, Adulterated, OTC.
From the letter: “you do not test each batch of finished drug product for conformance to product release specifications before each batch release.”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 2 findings · 2 issue types
- Response due
- Fifteen (15) business days of receipt
- FDA asks for
- 3 actions
- Named as possible actions
- Import alert, refusal of admission
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Laboratory controls & testing · 21 CFR 211.165(a)Finished drug product batches were released without appropriate laboratory testing, including sterility testing for products labeled as sterile.
you do not test each batch of finished drug product for conformance to product release specifications before each batch release. This includes not conducting sterility testing on your drug product purporting to be sterile.
02Production & process controls · 21 CFR 211.100(a)Manufacturing processes lacked written procedures and process validation studies, including for sterility.
your firm does not have process validation procedures or process validation studies. This includes not conducting studies to demonstrate your process can ensure sterility of a drug product purporting to be sterile.
Additional FDA passages
2 extracted findingsSelected FDA passages, not the complete letter.
Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).
Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).
What FDA requested
- Engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate operations and assist in meeting CGMP requirements.
- Perform a comprehensive six-system audit of the entire operation for CGMP compliance.
- Evaluate the completion and efficacy of corrective actions and preventive actions before pursuing resolution of compliance status with FDA.
FDA Warning Letter
39 paragraphs · 6 sectionsText as published on FDA.gov, retrieved Nov 18, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
1Introduction
1 paragraph
This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.
2FDA Review
4 paragraphs
Violations were identified and documented during review of your drug manufacturing facility, Shenzhen Benliju Biotech Co., Ltd., FDA Establishment Identifier (FEI) 3013504845. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.
Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 20, 2026 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.
This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).
Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).
3Violations of the Federal Food, Drug, and Cosmetic Act
14 paragraphs
The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.
1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).
Your firm manufactures OTC drug products such as (b)(4) which are labeled as “sterile.” Based on the records and information provided, you do not demonstrate that you conduct adequate finished drug product testing including microbiological tests on your OTC drug products. For example, you indicate that you do not test each batch of finished drug product for conformance to product release specifications before each batch release. This includes not conducting sterility testing on your drug product purporting to be sterile.
Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.
2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).
Based on the records and information you provided, you do not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. Specifically, your response states that your firm does not have process validation procedures or process validation studies. This includes not conducting studies to demonstrate your process can ensure sterility of a drug product purporting to be sterile.
Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.
Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.
See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https://www.fda.gov/media/71021/download.
3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).
Based on the records and information you provided, you do not demonstrate that your quality unit (QU) has adequately exercised its responsibilities and authority for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:
Adequate laboratory control procedures to ensure that drug products conform to appropriate standards of identity, strength, quality and purity (21 CFR 211.160(b)).
The establishment of an adequate ongoing stability program (21 CFR 211.166(a)).
Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download.
4Drug Recall
1 paragraph
On October 21, 2026, FDA held a teleconference with you, recommending that you recall all lots of (b)(4) you manufactured, within expiry, which are labeled as “sterile” as you have not demonstrated that these products are in fact sterile. On October 22, 2026, you agreed to the recall.
5CGMP Consultant Recommended
2 paragraphs
Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.
Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.
6Conclusion
6 paragraphs
As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.
FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on September 30, 2026.
FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.
Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Shenzhen Benliju Biotech Co., Ltd., at Factory Building 303, Qihong Pinshun Industrial Park, 105 Pinshun Road, Guixiang Community, Guanlan Street, Shenzhen, Guangdong 518000, China into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your written response with FEI 3013504845 and ATTN: Rory Geyer in the subject line of the email.
FDA posts warning letters to www.FDA.gov.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
Regulations
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- Shenzhen Shi, Guangdong Sheng, China
- Letter posted date
- Nov 17, 2026
- Letter issue date
- Nov 6, 2026
- Addressed to
- General Manager
- Inspection dates
- Not recorded
- Response window
- 15 business days after receipt of this letter
Read the source clause
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter.
- Record length
- 1,392 words · 3 recorded redactions
- Published status
- No published close-out
- FDA reference
- 320-27-21
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 19, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.